131 related articles for article (PubMed ID: 38049963)
1. Novel Biodistribution of PSMA Radiotracer in the Uvula of Patients Undergoing PSMA PET/CT.
Philbrook P; Casano KR; Lee DJ
Clin Nucl Med; 2024 Feb; 49(2):e80-e81. PubMed ID: 38049963
[TBL] [Abstract][Full Text] [Related]
2. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
3. Normal distribution pattern and physiological variants of 68Ga-PSMA-11 PET/CT imaging.
Demirci E; Sahin OE; Ocak M; Akovali B; Nematyazar J; Kabasakal L
Nucl Med Commun; 2016 Nov; 37(11):1169-79. PubMed ID: 27333090
[TBL] [Abstract][Full Text] [Related]
4. The Theranostic PSMA Ligand PSMA-617 in the Diagnosis of Prostate Cancer by PET/CT: Biodistribution in Humans, Radiation Dosimetry, and First Evaluation of Tumor Lesions.
Afshar-Oromieh A; Hetzheim H; Kratochwil C; Benesova M; Eder M; Neels OC; Eisenhut M; Kübler W; Holland-Letz T; Giesel FL; Mier W; Kopka K; Haberkorn U
J Nucl Med; 2015 Nov; 56(11):1697-705. PubMed ID: 26294298
[TBL] [Abstract][Full Text] [Related]
5. Biodistribution of [(68)Ga]PSMA-HBED-CC in Patients with Prostate Cancer: Characterization of Uptake in Normal Organs and Tumour Lesions.
Prasad V; Steffen IG; Diederichs G; Makowski MR; Wust P; Brenner W
Mol Imaging Biol; 2016 Jun; 18(3):428-36. PubMed ID: 27038316
[TBL] [Abstract][Full Text] [Related]
6. How accurate is
Erdem S; Simsek DH; Degirmenci E; Aydin R; Bagbudar S; Ozluk Y; Sanli Y; Sanli O; Ozcan F
Urol Oncol; 2022 Jan; 40(1):6.e1-6.e9. PubMed ID: 34400066
[TBL] [Abstract][Full Text] [Related]
7. [
Rosar F; Schaefer-Schuler A; Bartholomä M; Maus S; Petto S; Burgard C; Privé BM; Franssen GM; Derks YHW; Nagarajah J; Khreish F; Ezziddin S
Eur J Nucl Med Mol Imaging; 2022 Nov; 49(13):4736-4747. PubMed ID: 35930033
[TBL] [Abstract][Full Text] [Related]
8. PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions.
Afshar-Oromieh A; Malcher A; Eder M; Eisenhut M; Linhart HG; Hadaschik BA; Holland-Letz T; Giesel FL; Kratochwil C; Haufe S; Haberkorn U; Zechmann CM
Eur J Nucl Med Mol Imaging; 2013 Apr; 40(4):486-95. PubMed ID: 23179945
[TBL] [Abstract][Full Text] [Related]
9.
von Eyben FE; Picchio M; von Eyben R; Rhee H; Bauman G
Eur Urol Focus; 2018 Sep; 4(5):686-693. PubMed ID: 28753806
[TBL] [Abstract][Full Text] [Related]
10. A prospective randomized multicentre study of the impact of gallium-68 prostate-specific membrane antigen (PSMA) PET/CT imaging for staging high-risk prostate cancer prior to curative-intent surgery or radiotherapy (proPSMA study): clinical trial protocol.
Hofman MS; Murphy DG; Williams SG; Nzenza T; Herschtal A; Lourenco RA; Bailey DL; Budd R; Hicks RJ; Francis RJ; Lawrentschuk N
BJU Int; 2018 Nov; 122(5):783-793. PubMed ID: 29726071
[TBL] [Abstract][Full Text] [Related]
11. Risk of metastatic disease on
Yaxley JW; Raveenthiran S; Nouhaud FX; Samaratunga H; Yaxley WJ; Coughlin G; Yaxley AJ; Gianduzzo T; Kua B; McEwan L; Wong D
BJU Int; 2019 Sep; 124(3):401-407. PubMed ID: 31141284
[TBL] [Abstract][Full Text] [Related]
12. Comparison of
Regula N; Kostaras V; Johansson S; Trampal C; Lindström E; Lubberink M; Velikyan I; Sörensen J
Sci Rep; 2020 Mar; 10(1):4993. PubMed ID: 32193430
[TBL] [Abstract][Full Text] [Related]
13. Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Compared with Conventional Imaging for Initial Staging of Treatment-naïve Intermediate- and High-risk Prostate Cancer: A Retrospective Single-center Study.
Lenis AT; Pooli A; Lec PM; Sadun TY; Johnson DC; Lebacle C; Fendler WP; Eiber M; Czernin J; Reiter RE; Calais J
Eur Urol Oncol; 2022 Oct; 5(5):544-552. PubMed ID: 32958451
[TBL] [Abstract][Full Text] [Related]
14. Diagnostic performance of Gallium-68 prostate-specific membrane antigen positron emission tomography-computed tomography in intermediate and high risk prostate cancer.
El Hajj A; Yacoub B; Mansour M; Khauli R; Bulbul M; Nassif S; Haidar MB
Medicine (Baltimore); 2019 Nov; 98(44):e17491. PubMed ID: 31689752
[TBL] [Abstract][Full Text] [Related]
15. 68Ga-labeled PSMA-11 (68Ga-isoPROtrace-11) synthesized with ready to use kit: normal biodistribution and uptake characteristics of tumour lesions.
Kurash MM; Gill R; Khairulin M; Harbosh H; Keidar Z
Sci Rep; 2020 Feb; 10(1):3109. PubMed ID: 32080309
[TBL] [Abstract][Full Text] [Related]
16. In vitro and in vivo comparative study of a novel
Chen H; Cai P; Feng Y; Sun Z; Wang Y; Chen Y; Zhang W; Liu N; Zhou Z
Sci Rep; 2021 Sep; 11(1):19122. PubMed ID: 34580375
[No Abstract] [Full Text] [Related]
17. Primary lymph-node staging with
Corona-Montes VE; González-Cuenca E; Fernández-Noyola G; Olarte-Casas MA; Bobadilla-Salazar D; Medrano-Urtecho HM; Asimakopoulos AD
Urol Oncol; 2021 Aug; 39(8):494.e1-494.e6. PubMed ID: 33223371
[TBL] [Abstract][Full Text] [Related]
18. Tumor Sink Effect in
Gafita A; Wang H; Robertson A; Armstrong WR; Zaum R; Weber M; Yagubbayli F; Kratochwil C; Grogan TR; Nguyen K; Navarro F; Esfandiari R; Rauscher I; Menze B; Elashoff D; Delpassand ES; Herrmann K; Czernin J; Hofman MS; Calais J; Fendler WP; Eiber M
J Nucl Med; 2022 Feb; 63(2):226-232. PubMed ID: 34049987
[TBL] [Abstract][Full Text] [Related]
19.
García Garzón JR; de Arcocha Torres M; Delgado-Bolton R; Ceci F; Alvarez Ruiz S; Orcajo Rincón J; Caresia Aróztegui AP; García Velloso MJ; García Vicente AM;
Rev Esp Med Nucl Imagen Mol (Engl Ed); 2018; 37(2):130-138. PubMed ID: 28941866
[TBL] [Abstract][Full Text] [Related]
20. Antihormonal-Treatment Status Affects
Kluge K; Haberl D; Einspieler H; Rasul S; Gutschmayer S; Kenner L; Kramer G; Grubmüller B; Shariat S; Haug A; Hacker M
J Nucl Med; 2023 Nov; 64(11):1730-1736. PubMed ID: 37734840
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
